CS logo
small CS logo
Mater Misericordiae University Hospital, Institute for Cancer Research

Dublin, Ireland

About Mater Misericordiae University Hospital, Institute for Cancer Research


  • Top Sponsors
  • Top Collaborators
  • Trials By Phase
  • Recruitment Status
  • Top Conditions
  • Intervention Types
  • Top Intervention Names
  • Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
1
Puma Biotechnology, Inc.
1
Total Rows: 2

Clinical Trials at Mater Misericordiae University Hospital, Institute for Cancer Research


During the past decade, Mater Misericordiae University Hospital, Institute for Cancer Research conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.
Created with Highcharts 11.1.0TrialsTrials Trend - Last 10 Years110011000000Started TrialsCompleted Trails20172018201900.511.5
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment

Rows per page:

0–0 of 0

Clinical Trials Sponsors and Collaborators


Created with Highcharts 11.1.0Top Leading SponsorsHoffmann-La Roche: 1Hoffmann-La Roche: 1Puma Biotechnology, Inc.: 1Puma Biotechnology, Inc.: 1

Created with Highcharts 11.1.0Top Collaborators

Clinical Trials Conditions at Mater Misericordiae University Hospital, Institute for Cancer Research


According to Clinical.Site data, the most researched conditions in "Mater Misericordiae University Hospital, Institute for Cancer Research" are "Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer" (1 trials), "Metastatic Cervical Cancer" (1 trials) and "Non-Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Mater Misericordiae University Hospital, Institute for Cancer Research" in a lesser frequency.

Clinical Trials Intervention Types at Mater Misericordiae University Hospital, Institute for Cancer Research


Most popular intervention types in "Mater Misericordiae University Hospital, Institute for Cancer Research" are "Diagnostic Test" (1 trials) and "Drug" (1 trials). Other intervention types were less common.
The name of intervention was led by "Almac HER-Seq Assay" (1 trials), "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody" (1 trials), "Gemcitabine" (1 trials) and "Vinorelbine" (1 trials). Other intervention names were less common.

Clinical Trials Genders at Mater Misericordiae University Hospital, Institute for Cancer Research


The vast majority of trials in "Mater Misericordiae University Hospital, Institute for Cancer Research" are 2 trials for "All" genders.

Clinical Trials Status at Mater Misericordiae University Hospital, Institute for Cancer Research


Currently, there are NaN active trials in "Mater Misericordiae University Hospital, Institute for Cancer Research". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Mater Misericordiae University Hospital, Institute for Cancer Research, undefined suspended trials, and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Mater Misericordiae University Hospital, Institute for Cancer Research, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".
Created with Highcharts 11.1.0Trials By PhasePhase 3: 1Phase 3: 1

Created with Highcharts 11.1.0Trials StatusActive, not recruiting: 1Active, not recruiting: 1Terminated: 1Terminated: 1